Macquarie Group LTD Viking Therapeutics, Inc. Transaction History

Macquarie Group LTD

  • $90.3 Billion
  • Q3 2024

A detailed history of Macquarie Group LTD transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 568,400 shares of VKTX stock, worth $24.2 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
568,400
Previous 568,706 0.05%
Holding current value
$24.2 Million
Previous $30.1 Million 19.37%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$49.84 - $70.47 $15,251 - $21,563
-306 Reduced 0.05%
568,400 $36 Million
Q2 2024

Aug 09, 2024
BUY
$47.39 - $80.2 $4.35 Million - $7.36 Million
91,771 Added 19.24%
568,706 $30.1 Million
Q1 2024

May 14, 2024
BUY
$17.4 - $94.5 $2.55 Million - $13.9 Million
146,835 Added 44.48%
476,935 $39.1 Million
Q2 2022

Aug 15, 2022
SELL
$2.11 - $3.15 $4,110 - $6,136
-1,948 Reduced 0.59%
330,100 $954,000
Q1 2021

May 14, 2021
SELL
$5.74 - $9.67 $3,426 - $5,772
-597 Reduced 0.18%
332,048 $2.1 Million
Q2 2020

Aug 11, 2020
BUY
$4.35 - $8.08 $11,070 - $20,563
2,545 Added 0.77%
332,645 $2.4 Million
Q2 2019

Aug 14, 2019
SELL
$7.67 - $10.63 $553,820 - $767,549
-72,206 Reduced 17.95%
330,100 $2.74 Million
Q1 2019

May 15, 2019
SELL
$7.58 - $9.94 $269,802 - $353,804
-35,594 Reduced 8.13%
402,306 $4 Million
Q4 2018

Feb 15, 2019
BUY
$7.16 - $16.21 $437,476 - $990,431
61,100 Added 16.22%
437,900 $3.35 Million
Q3 2018

Nov 15, 2018
BUY
$9.7 - $19.65 $452,989 - $917,654
46,700 Added 14.15%
376,800 $6.56 Million
Q2 2018

Aug 14, 2018
BUY
$3.88 - $12.74 $1.28 Million - $4.21 Million
330,100 New
330,100 $3.13 Million
Q1 2018

May 11, 2018
SELL
$4.11 - $6.93 $8,631 - $14,553
-2,100 Closed
0 $0
Q4 2017

Feb 15, 2018
BUY
$1.74 - $4.34 $3,654 - $9,114
2,100
2,100 $9,000

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.26B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email